Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-Vax (Hadassah Medical Organization)
- Development stage
- Unknown
- Lead developer
- Hadassah Medical Organization
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**M-Vax** is an investigational personalized whole-cell therapeutic cancer vaccine evaluated by Hadassah Medical Organization in patients with metastatic melanoma and epithelial malignancies. The product consists of laboratory-expanded autologous or allogeneic tumor cells that are modified with dinitrophenyl to enhance immunogenicity, irradiated to prevent proliferation, and administered repeatedly to stimulate patient-specific antitumor immune responses against tumor-associated antigens.
- Other names
- Autologous and Allogeneic Whole Cell Cancer VaccineDNP-modified tumor cell vaccine
Beyond the preview
Go deeper on M-Vax (Hadassah Medical Organization).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M-Vax (Hadassah Medical Organization).